Skip to main content

Foghorn Therapeutics Inc.

FHTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001822462

No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 102 institutions reported holding it in 13F filings for Q2 2026, worth $219.2M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Foghorn Therapeutics Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of FHTX: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders4539−6
Shares23.3M23.9M+588.7K (+2.5%)
Value$306.7M$255.1M−$51.5M (−16.8%)

New holders (3)

Institutions that held Foghorn Therapeutics Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to FHTX in Q2 2021
InstitutionSharesValue% of portfolio
Rhumbline Advisers15,659$167.0K0.00%
NewSquare Capital LLC5,000$53.0K0.01%
Signaturefd, LLC76$1.00K0.00%

Sold out (9)

Institutions that held Foghorn Therapeutics Inc. at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of FHTX in Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Cormorant Asset Management, LP1,000,000$13.2M
Point72 Asset Management, L.P.109,200$1.44M
Pictet Asset Management Ltd98,085$1.29M
Octagon Capital Advisors LP69,132$911.0K
Board of Trustees of The Leland Stanford Junior University30,657$404.0K
Victory Capital Management Inc16,190$213.0K
UBS Group AG2,136$28.0K
TFC Financial Management280$4.00K
Bank of Montreal222$3.00K